Comment diagnostiquer une endométriose ?

L'endométriose se diagnostique par échographie, IRM ou laparoscopie.

Quels tests pour les fibromes utérins ?

Les fibromes sont souvent diagnostiqués par échographie ou hystéroscopie.

Quels symptômes indiquent une chirurgie ?

Des douleurs persistantes, des saignements anormaux ou des masses pelviennes peuvent nécessiter une chirurgie.

Comment évaluer une infection pelvienne ?

L'infection pelvienne se diagnostique par examen clinique et tests sanguins.

Quel rôle des biopsies dans le diagnostic ?

Les biopsies permettent d'analyser les tissus et de confirmer des pathologies.

Quels sont les symptômes de l'endométriose ?

Les symptômes incluent douleurs pelviennes, règles douloureuses et infertilité.

Comment reconnaître un fibrome utérin ?

Les fibromes peuvent causer des saignements abondants et des douleurs pelviennes.

Quels signes d'infection gynécologique ?

Fièvre, douleurs abdominales et pertes vaginales anormales sont des signes d'infection.

Quels symptômes d'une grossesse extra-utérine ?

Douleurs abdominales unilatérales et saignements vaginaux peuvent indiquer une grossesse extra-utérine.

Quels symptômes d'un cancer de l'ovaire ?

Ballonnements, douleurs pelviennes et changements d'appétit peuvent signaler un cancer de l'ovaire.

Comment prévenir l'endométriose ?

Il n'existe pas de méthode garantie, mais un suivi médical régulier peut aider.

Quelles mesures pour éviter les fibromes ?

Maintenir un poids santé et une alimentation équilibrée peut réduire le risque de fibromes.

Comment réduire le risque d'infections ?

Pratiquer des rapports protégés et maintenir une bonne hygiène intime aide à prévenir les infections.

Y a-t-il des moyens de prévenir le cancer de l'ovaire ?

Un suivi régulier et des antécédents familiaux peuvent aider à la détection précoce.

Comment éviter les complications post-chirurgicales ?

Suivre les recommandations médicales et éviter les efforts excessifs aide à prévenir les complications.

Quelles sont les options chirurgicales pour l'endométriose ?

Les options incluent la laparoscopie pour retirer les lésions et l'hystérectomie.

Comment traiter les fibromes utérins ?

Les traitements incluent la myomectomie, l'hystérectomie ou des médicaments hormonaux.

Quel est le rôle de la laparoscopie ?

La laparoscopie permet de diagnostiquer et traiter diverses affections gynécologiques.

Quand envisager une hystérectomie ?

Une hystérectomie est envisagée en cas de fibromes, cancer ou saignements anormaux persistants.

Quels traitements pour les infections pelviennes ?

Les infections pelviennes sont traitées par antibiotiques et parfois chirurgie.

Quelles complications peuvent survenir après une hystérectomie ?

Les complications incluent infections, saignements et problèmes urinaires.

Quels risques après une laparoscopie ?

Les risques incluent des lésions d'organes, infections et douleurs persistantes.

Comment gérer les complications d'une chirurgie gynécologique ?

Un suivi médical régulier et une communication ouverte avec le médecin sont essentiels.

Quelles sont les complications possibles des fibromes ?

Les fibromes peuvent causer des douleurs, des saignements et des complications pendant la grossesse.

Quels effets secondaires des traitements hormonaux ?

Les traitements hormonaux peuvent entraîner des nausées, des saignements irréguliers et des changements d'humeur.

Quels sont les facteurs de risque de l'endométriose ?

Les facteurs incluent des antécédents familiaux, des menstruations précoces et des cycles menstruels longs.

Quels facteurs augmentent le risque de fibromes ?

L'obésité, les antécédents familiaux et les déséquilibres hormonaux augmentent le risque de fibromes.

Comment l'âge influence-t-il les risques gynécologiques ?

Le risque de nombreuses affections gynécologiques augmente avec l'âge, surtout après 30 ans.

Quels sont les facteurs de risque d'infections pelviennes ?

Les rapports sexuels non protégés et les antécédents d'infections augmentent le risque.

Quels facteurs influencent le cancer de l'ovaire ?

Les antécédents familiaux, l'âge avancé et certains syndromes génétiques augmentent le risque.

Procédures de chirurgie gynécologique - Informations médicales vérifiées

Serum prostate specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia.

15 Dec 2022

DOI: 10.4102/phcfm.v14i1.3736 PMID: 36546488

Benign prostatic hyperplasia (BPH) is the most common cause of bladder outlet obstruction in men over the age of 50 years. An association between the prostate specific antigen (PSA), International Pro... To determine the correlation between the PSA, IPSS and PV in men of African descent.... This was a cross sectional analysis involving 92 patients diagnosed as having symptomatic BPH at the Ho Teaching Hospital.... The data were collected using standardised questionnaires. The IPSS determined urinary symptom severity. The PV was determined using a transabdominal ultrasound machine. Serum PSA was retrieved from t... The mean PV was 61.04 cm3 ± 21.95 cm3, the mean PSA was 4.21 ng/mL ± 3.85 ng/mL, and mean IPSS of 21.59 ± 3.78. The Pearson's correlation between PV and PSA was 0.283 (p = 0.01), between PV and IPSS w... This study showed that serum PSA has a positive correlation with PV. However, IPSS had no significant association with PSA or PV in patients with BPH.Contribution: This study provides insights into th...

Male Humans Middle Aged Prostatic Hyperplasia Prostate-Specific Antigen +2 autres

Granulomatous prostatitis: mimicking locally advanced prostate adenocarcinoma.

17 10 2023

DOI: 10.23750/abm.v94i5.13751 PMID: 37850783

We report the case of a 63-year-old male who came to the urology clinic with an increasing value of the prostate specific antigen and an asymmetrical enlargement at the digital rectal examination. The...

Male Humans Middle Aged Prostatitis Prostate +5 autres

Prostatic Artery Embolization Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Cost-Effectiveness Analysis.

12 2022

DOI: 10.1016/j.jvir.2022.08.006 PMID: 35964881

To compare the cost effectiveness of prostatic artery embolization (PAE) with that of transurethral resection of the prostate (TURP) for the treatment of medically refractory benign prostatic hyperpla... A cost-effectiveness analysis with Markov modeling was performed, comparing the clinical course after PAE with that after TURP for 3 years. Probabilities were obtained from the available literature, a... Base case calculation showed comparable outcomes (PAE, 2.845 QALY; TURP, 2.854 QALY), with a cost difference of $3,104 (PAE, $2,934; TURP, $6,038). The incremental cost-effectiveness ratio was $360,24... PAE is a cost-effective strategy to treat medically refractory BPH, resulting in comparable health benefits at a lower cost than that of TURP even when accounting for extreme alterations in adverse ev...

Aged United States Male Humans Prostatic Hyperplasia +7 autres

Prostate organogenesis.

15 06 2022

DOI: 10.1242/dev.200394 PMID: 35726824

Prostate organogenesis begins during embryonic development and continues through puberty when the prostate becomes an important exocrine gland of the male reproductive system. The specification and gr...

Androgens Epithelial Cells Epithelium Humans Male +3 autres

Prostatic Urethral Length as a Predictor for Surgery in Benign Prostatic Hyperplasia.

10 Mar 2023

DOI: 10.33314/jnhrc.v20i3.4613 PMID: 36974872

Benign prostatic hyperplasia is associated with structural and morphological changes including elongation of prostatic urethral length. The aim of our study was to assess whether prostatic urethral le... This prospective observational study was conducted over a 12-months duration. All the patients who presented with lower urinary tract symptoms secondary to benign prostatic hyperplasia were evaluated ... A total of 153 patients were included in the study. Eighty-three (54.2%) patients underwent surgery during the study period. Prostate volume, intravesical prostatic protrusion, post-void residual volu... BPH patients with longer PUL may require surgical management. PUL measured by TRUS may be a predicting factor for the need of surgery in BPH Keywords: Benign prostatic hyperplasia; lower urinary tract...

Male Humans Prostate Prostatic Hyperplasia Prostate-Specific Antigen +2 autres

Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.

27 Dec 2022

DOI: 10.1186/s12957-022-02841-6 PMID: 36572885

Biomarkers of DNA damage repair deficiency provide opportunities for personalized treatment with immunotherapy. However, there is limited research on the immune microenvironment of adeno-neuroendocrin... A retrospective medical record review of 66 patients with prostate cancer (PCa) was performed. PCa samples from the 66 patients were analyzed using immunohistochemical staining for the detection of ch... Twenty patients presented with adeno-NEPC, whereas 46 presented with adeno-PCa. The median age of patients at PCa diagnosis was 67.86 ± 7.05 years (68.65 ± 7.23 years, adeno-NEPC; 67.52 ± 7.02 years, ... Our study revealed clinicopathological manifestations of adeno-NEPC and some possible predictive factors significantly associated with better outcomes in patients with adeno-NEPC. These findings might...

Male Humans Middle Aged Aged Prostatic Neoplasms +7 autres

The influence of prostate volume on clinical parameters in prostate cancer screening.

Oct 2022

DOI: 10.1002/jcla.24700 PMID: 36098911

The purpose of the study was to evaluate the diagnostic significance of two new and a few clinical markers for prostate cancer (PCa) at various prostate volumes (PV).... The study subjects were divided into two groups. Among them, there were 70 cases in the PV ≤30 ml group (benign prostatic hyperplasia [BPH]: 32 cases, PCa: 38 cases) and 372 cases in the PV > 30 ml gr... In the PV ≤30 ml group, the diagnostic parameters based on prostate-specific antigen (PSA) had a decreased diagnostic significance for PCa. In the PV > 30 ml group, PSAD (AUC = 0.709), AVR (AVR = Age/... Choosing appropriate indicators for different PVs could contribute to the early screening and diagnosis of PCa. The difference in the diagnostic value of two new indicators (A-PSAD and AVR), and PSAD ...

Biomarkers Early Detection of Cancer Humans Male Prostate +4 autres

Relationships between holmium laser enucleation of the prostate and prostate cancer.

04 2023

DOI: 10.1038/s41585-022-00678-y PMID: 36418491

Holmium laser enucleation of the prostate (HoLEP) is a size-independent surgical option for treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) with excellent, durable ...

Male Humans Prostate Prostatic Hyperplasia Prostate-Specific Antigen +7 autres

Prostate health index (PHI) as an accurate prostate cancer predictor.

Sep 2023

DOI: 10.1007/s00432-023-04860-6 PMID: 37204514

This study aims to compare the ability of the PHI versus tPSA test to predict the presence of PCa in our population.... A prospective observational study was performed. We included patients with tPSA ≥ 2.5 ng/ml, biopsy naïve or previous negative biopsy, undergoing a blood test, which includes tPSA, fPSA, and p2PSA, an... 140 men were included. Fifty-seven (40.7%) had a positive prostate biopsy result (Group A), and 83 (59.3%) had a negative biopsy result (Group B). The mean age was similar in both groups (mean ± stand... The PHI test improves PCa detection compared to tPSA in our population....

Male Humans Prostate-Specific Antigen Prostate Prostatic Neoplasms +3 autres

Prostate Health Index Density Outperforms Prostate-specific Antigen Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging of the Prostate: A Multicenter Evaluation.

Jul 2023

DOI: 10.1097/JU.0000000000003450 PMID: 37036248

We compare Prostate Health Index, Prostate Health Index density, and PSA density in predicting clinically significant prostate cancer in MRI-guided prostate biopsy.... This is a multicenter evaluation of prospectively maintained prostate biopsy databases at 10 urology centers. Men with Prostate Health Index and MRI-guided targeted and systematic prostate biopsy perf... A total of 1,215 men were analyzed. Prostate cancer and clinically significant prostate cancer were diagnosed in 51% (617/1,215) and 35% (422/1,215) of men, respectively. Clinically significant prosta... Prostate Health Index density outperformed Prostate Health Index or PSA density in clinically significant prostate cancer detection in men with multiparametric MRI performed, and further reduced unnec...

Male Humans Prostatic Neoplasms Prostate Prostate-Specific Antigen +3 autres

Procédures de chirurgie gynécologique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Questions fréquentes et termes MeSH associés

Diagnostic 5

Symptômes 5

Prévention 5

Traitements 5

Complications 5

Facteurs de risque 5

Contenu validé par Dr Olivier Menir

Sous-catégories

Colposcopie

Colpotomie

Culdoscopie

Dilatation et curetage

Techniques d'ablation de l'endomètre

Hystérectomie

Hystéroscopie

Ovariectomie

Salpingectomie

Salpingostomie

Embolisation d'artère utérine

Myomectomie de l'utérus

Vulvectomie

Curetage aspiratif

Hystérectomie vaginale

Trachélectomie

Salpingo-ovariectomie

Auteurs principaux

Sources (10000 au total)